Sanofi Needs Acquisitions to Overcome Pipeline Disappointments -- Market Talk

Dow Jones05-07

0647 GMT - Sanofi needs mergers and acquisitions to overcome several late-stage pipelines disappointments and has the means to pursue them, Berenberg analysts say in a research note. The French drugmaker has spent more than 11 billion euros on acquisitions over the past year and has the capacity to deploy about 15 billion euros, according to Berenberg. This could be stretched to about 25 billion euros if Sanofi targets companies with drugs already on the market, Berenberg says. "Sanofi's ability to offset the Dupixent loss of exclusivity has diminished in the eyes of investors with a pivot back towards the Regeneron collaboration for a solution," the analysts say. "We would like to see Sanofi execute bolt-ons in clinical stage companies specializing in immunology, rare disease, neurology and oncology." (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

May 07, 2026 02:47 ET (06:47 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2633197501?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 14:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633197501","market":"hk","top_or_hot":-1,"title":"Sanofi Needs Acquisitions to Overcome Pipeline Disappointments -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0647 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> needs mergers and acquisitions to overcome several late-stage pipelines disappointments and has the means to pursue them, Berenberg analysts say in a research note. The French drugmaker has spent more than 11 billion euros on acquisitions over the past year and has the capacity to deploy about 15 billion euros, according to Berenberg. This could be stretched to about 25 billion euros if <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> targets companies with drugs already on the market, Berenberg says. \"Sanofi's ability to offset the Dupixent loss of exclusivity has diminished in the eyes of investors with a pivot back towards the Regeneron collaboration for a solution,\" the analysts say. \"We would like to see Sanofi execute bolt-ons in clinical stage companies specializing in immunology, rare disease, neurology and oncology.\" (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 07, 2026 02:47 ET (06:47 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Needs Acquisitions to Overcome Pipeline Disappointments -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Needs Acquisitions to Overcome Pipeline Disappointments -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-07 14:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0647 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> needs mergers and acquisitions to overcome several late-stage pipelines disappointments and has the means to pursue them, Berenberg analysts say in a research note. The French drugmaker has spent more than 11 billion euros on acquisitions over the past year and has the capacity to deploy about 15 billion euros, according to Berenberg. This could be stretched to about 25 billion euros if <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> targets companies with drugs already on the market, Berenberg says. \"Sanofi's ability to offset the Dupixent loss of exclusivity has diminished in the eyes of investors with a pivot back towards the Regeneron collaboration for a solution,\" the analysts say. \"We would like to see Sanofi execute bolt-ons in clinical stage companies specializing in immunology, rare disease, neurology and oncology.\" (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 07, 2026 02:47 ET (06:47 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNYNF","symbol_name":"Sanofi","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2633197501","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2633197501","pubTimestamp":1778136420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0647 GMT - Sanofi needs mergers and acquisitions to overcome several late-stage pipelines disappointments and has the means to pursue them, Berenberg analysts say in a research note. The French drugmaker has spent more than 11 billion euros on acquisitions over the past year and has the capacity to deploy about 15 billion euros, according to Berenberg. This could be stretched to about 25 billion euros if Sanofi targets companies with drugs already on the market, Berenberg says. \"Sanofi's ability to offset the Dupixent loss of exclusivity has diminished in the eyes of investors with a pivot back towards the Regeneron collaboration for a solution,\" the analysts say. \"We would like to see Sanofi execute bolt-ons in clinical stage companies specializing in immunology, rare disease, neurology and oncology.\" ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNYNF":"Sanofi","BK4588":"碎股","BK4585":"ETF&股票定投概念","SNY":"赛诺菲安万特","BK4007":"制药","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC"},"translate_title":"赛诺菲需要收购来克服管道失望——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNYNF":1.5,"SNY":0.9},"content_text":"0647 GMT - Sanofi needs mergers and acquisitions to overcome several late-stage pipelines disappointments and has the means to pursue them, Berenberg analysts say in a research note. The French drugmaker has spent more than 11 billion euros on acquisitions over the past year and has the capacity to deploy about 15 billion euros, according to Berenberg. This could be stretched to about 25 billion euros if Sanofi targets companies with drugs already on the market, Berenberg says. \"Sanofi's ability to offset the Dupixent loss of exclusivity has diminished in the eyes of investors with a pivot back towards the Regeneron collaboration for a solution,\" the analysts say. \"We would like to see Sanofi execute bolt-ons in clinical stage companies specializing in immunology, rare disease, neurology and oncology.\" (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 07, 2026 02:47 ET (06:47 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2633197501","isCrawlerRequest":true}